A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers

Exclusion Criteria

• •History of myocardial infarction or unstable angina within 6 months prior to enrollment, troponin levels consistent with myocardial infarction, or clinically significant cardiac disease, such as ventricular arrhythmia requiring therapy, uncontrolled hypertension, or any history of symptomatic congestive heart failure (CHF)
• •Clinically significant infiltrative pulmonary disease not related to lung metastases
• •Active hepatitis B or hepatitis C infection or other known chronic liver disease
• •Acute or chronic uncontrolled renal disease, pancreatitis, or liver disease (with exception of patients with Gilbert's Syndrome, asymptomatic gall stones, liver metastases, or stable chronic liver disease per investigator assessment)
• •Known history of human immunodeficiency virus (HIV) infection
• •Brain metastases: Untreated CNS metastases, symptomatic CNS metastases, or radiation treatment for CNS metastases within 4 weeks of start of study treatment. Stable, treated brain metastases are allowed (defined as patients who are off steroids and anticonvulsants and are stable for at least 1 month at the time of screening).
• •Known leptomeningeal disease (LMD)